Company / Depreciation & Amortization
Jade Biosciences, Inc. Depreciation & Amortization History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$282.0K
FY2024
5-year range
$1.0K / $282.0K
FY2020-FY2024
Trend
+193.8%
vs FY2023
Sector context
#168 of 192
Health Care
What the data says
Jade Biosciences, Inc.'s depreciation & amortization of $282,000 is lower than 87% of companies in the Health Care sector (FY2024). Depreciation & Amortization has increased for 4 consecutive years, from $1,000 in FY2020 to $282,000 in FY2024.
Based on SEC 10-K filings.
$282,000 in FY2024 with a 3-year CAGR of +165.9%.
Increased from $68,000 to $282,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +165.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-99.9% below sector average
Key checks
Key Insights
- Jade Biosciences, Inc.'s depreciation & amortization has grown for 4 consecutive years.
- 3-year CAGR of +165.9%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 193.8% year-over-year.
- Ranks #168 out of 192 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $282.0K | +193.8% |
| FY2023 | $96.0K | +41.2% |
| FY2022 | $68.0K | +353.3% |
| FY2021 | $15.0K | +1400.0% |
| FY2020 | $1.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026